TY - JOUR
T1 - Serious infections caused by methicillin-resistant Staphylococcus aureus
AU - Boucher, Helen
AU - Miller, Loren G.
AU - Razonable, Raymund R.
N1 - Funding Information:
Potential conflicts of interest. H.B. has served as an adviser and consultant for Astellas/Theravance, Basilea, Cubist, Durata, Johnson & Johnson, Merck, Methylgene, Nabriva, Optimer, Rib-X, Targanta/TMC, and Wyeth. L.G.M. has received research grants from Pfizer and Cubist Pharmaceuticals and has served as a consultant for Pfizer, Theravance, and Forest Laboratories. R.R.R.: no conflicts. Financial support. Cubist Pharmaceuticals.
PY - 2010/9/15
Y1 - 2010/9/15
N2 - Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.
AB - Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.
UR - http://www.scopus.com/inward/record.url?scp=77957868388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957868388&partnerID=8YFLogxK
U2 - 10.1086/653519
DO - 10.1086/653519
M3 - Review article
C2 - 20731576
AN - SCOPUS:77957868388
VL - 51
SP - S183-S197
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 2
ER -